Trial Profile
Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients With Previously Untreated High Grade Myelodysplastic Syndromes
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Omacetaxine mepesuccinate (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2024 Planned number of patients changed from 51 to 45.
- 16 Feb 2024 Planned primary completion date changed from 1 Jun 2025 to 14 Apr 2024.